The more a patient has to pay for medications, the less likely they are to take them. This was the finding of a new study showing how copayments may be a barrier to drugs to treat pulmonary arterial hypertension.

The American Heart Association 2022 Scientific Sessions included 35 late-breaking studies and 39 featured science sessions presented at the meeting in Chicago, Nov. 5-7. Here is the list of all these studies with links to more information on the data.

Manesh R. Patel, MD, chair of AHA Scientific Sessions program, explains what he saw as the top takeaways from AHA 2022.

The new analysis was presented at the AHA Scientific Sessions 2022 conference and simultaneously published in the Journal of the American College of Cardiology.

Bhatt succeeds Valentin Fuster, MD, PhD, who has held the position since 2006 and will now serve in a more advisory role at Mount Sinai Heart.

While some heart failure medications are less effective in patients with concomitant atrial fibrillation, new research suggests that is not the case for dapagliflozin.

Patients impacted by this recall are advised to speak with a physician about how to proceed. 

Vaccine-related myocarditis was seen in approximately 0.00005% of children between the ages of 12 and 15. All cases were mild, and the median length of stay at the hospital was three days.